DOCSLIB.ORG

Brandname FDA # Approved Dosage Form Company ADVAIR DISKUS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brandname FDA # Approved Dosage Form Company ADVAIR DISKUS Brandname FDA # Approved Dosage Form Company ADVAIR DISKUS 100/50 021077 2000 POWDER; INHALATION GLAXOSMITHKLINE ALLERNAZE 020120 2000 SPRAY, METERED; NASAL LUPIN ATLANTIS ANDROGEL 021015 2000 GEL; TRANSDERMAL UNIMED PHARMS BIAXIN XL 050775 2000 TABLET, EXTENDED RELEASE; ORAL ABBOTT CONCERTA 021121 2000 TABLET, EXTENDED RELEASE; ORAL ORTHO MCNEIL JANSSEN DEPAKOTE ER 021168 2000 TABLET, EXTENDED RELEASE; ORAL ABBOTT DETROL LA 021228 2000 CAPSULE, EXTENDED RELEASE; ORAL PHARMACIA AND UPJOHN DOXIL 050718 2000 INJECTABLE, LIPOSOMAL; INJECTION ORTHO BIOTECH FLOVENT DISKUS 100 020833 2000 POWDER; INHALATION GLAXOSMITHKLINE GLUCOPHAGE XR 021202 2000 TABLET, EXTENDED RELEASE; ORAL BRISTOL MYERS SQUIBB LESCOL XL 021192 2000 TABLET, EXTENDED RELEASE; ORAL NOVARTIS MIRENA 021225 2000 INTRAUTERINE DEVICE; INTRAUTERINE BAYER NITROSTAT 021134 2000 TABLET; SUBLINGUAL PFIZER PHARMS PAXIL CR 020936 2000 TABLET, EXTENDED RELEASE; ORAL GLAXOSMITHKLINE PULMICORT RESPULES 020929 2000 SUSPENSION; INHALATION ASTRAZENECA QVAR 40 020911 2000 AEROSOL, METERED; INHALATION TEVA GLOBAL TRELSTAR DEPOT 020715 2000 INJECTABLE; INTRAMUSCULAR WATSON LABS VIADUR 021088 2000 IMPLANT; IMPLANTATION ALZA ZYPREXA ZYDIS 021086 2000 TABLET, ORALLY DISINTEGRATING; ORAL LILLY ACCUNEB 020949 2001 SOLUTION; INHALATION DEY ADDERALL XR 10 021303 2001 CAPSULE, EXTENDED RELEASE; ORAL SHIRE ADVICOR 021249 2001 TABLET, EXTENDED RELEASE; ORAL ABBOTT DUONEB 020950 2001 SOLUTION; INHALATION DEY KADIAN 020616 2001 CAPSULE, EXTENDED RELEASE; ORAL ACTAVIS ELIZABETH METADATE CD 021259 2001 CAPSULE, EXTENDED RELEASE; ORAL UCB INC ORTHO EVRA 021180 2001 FILM, EXTENDED RELEASE; TRANSDERMAL ORTHO MCNEIL JANSSEN PEGINTRON 103949 2001 VIAL SCHERING PROZAC WEEKLY 021235 2001 CAPSULE, DELAYED REL PELLETS; ORAL LILLY REMERON SOLTAB 021208 2001 TABLET, ORALLY DISINTEGRATING; ORAL ORGANON USA INC TOPROL-XL 019962 2001 TABLET, EXTENDED RELEASE; ORAL ASTRAZENECA TRELSTAR LA 021288 2001 INJECTABLE; INTRAMUSCULAR WATSON LABS VENTOLIN HFA 020983 2001 AEROSOL, METERED; INHALATION GLAXOSMITHKLINE ZOMIG-ZMT 021231 2001 TABLET, ORALLY DISINTEGRATING; ORAL ASTRAZENECA ZYRTEC-D 12 HOUR 021150 2001 TABLET, EXTENDED RELEASE; ORAL PFIZER ALTOPREV 021316 2002 TABLET, EXTENDED RELEASE; ORAL ANDRX LABS LLC AUGMENTIN XR 050785 2002 TABLET, EXTENDED RELEASE; ORAL GLAXOSMITHKLINE AVINZA 021260 2002 CAPSULE, EXTENDED RELEASE; ORAL KING PHARMS CIPRO XR 021473 2002 TABLET, EXTENDED RELEASE; ORAL BAYER HEALTHCARE CLARINEX REDITABS 021312 2002 TABLET, ORALLY DISINTEGRATING; ORAL SCHERING ELIGARD 22.5 MG 021379 2002 INJECTABLE; SUBCUTANEOUS SANOFI AVENTIS ELIGARD 7.5 021343 2002 INJECTABLE; SUBCUTANEOUS SANOFI AVENTIS US NEULASTA 125031 2002 SYRINGE AMGEN PEGASYS 103964 2002 SYRINGE HOFFMANN-LA ROCHE RITALIN LA 021284 2002 CAPSULE, EXTENDED RELEASE; ORAL NOVARTIS SUBOXONE 020733 2002 TABLET; SUBLINGUAL RECKITT BENCKISER SUBUTEX 020732 2002 TABLET; SUBLINGUAL RECKITT BENCKISER TESTIM 021454 2002 GEL; TRANSDERMAL AUXILIUM PHARMS XOPENEX 020837 2002 SOLUTION; INHALATION SEPRACOR ZERIT XR 021453 2002 CAPSULE, EXTENDED RELEASE; ORAL BRISTOL MYERS SQUIBB CARDIZEM LA 021392 2003 TABLET, EXTENDED RELEASE; ORAL BIOVAIL LABS INTL CLIMARA PRO 021258 2003 FILM, EXTENDED RELEASE; TRANSDERMAL BAYER HLTHC ESTRASORB 021371 2003 EMULSION; TOPICAL ESPRIT PHARMA FEMRING 021367 2003 INSERT, EXTENDED RELEASE; VAGINAL GALEN LTD FLUMIST 2003 NASAL MEDIMMUNE INNOPRAN XL 021438 2003 CAPSULE, EXTENDED RELEASE; ORAL RELIANT PHARMS KEMSTRO 021589 2003 TABLET, ORALLY DISINTEGRATING; ORAL SCHWARZ PHARMA OXYTROL 021351 2003 FILM, EXTENDED RELEASE; TRANSDERMAL WATSON LABS (UTAH) RISPERDAL CONSTA 021346 2003 INJECTABLE; INTRAMUSCULAR ORTHO MCNEIL JANSSEN RISPERDAL M-TAB 021444 2003 TABLET, ORALLY DISINTEGRATING; ORAL ORTHO MCNEIL JANSSEN RYTHMOL SR 021416 2003 CAPSULE, EXTENDED RELEASE; ORAL RELIANT PHARMS SOMAVERT 021106 2003 INJECTABLE; SUBCUTANEOUS PHARMACIA AND UPJOHN STRIANT 021543 2003 TABLET, EXTENDED RELEASE; BUCCAL COLUMBIA LABS UROXATRAL 021287 2003 TABLET, EXTENDED RELEASE; ORAL SANOFI AVENTIS US WELLBUTRIN XL 021515 2003 TABLET, EXTENDED RELEASE; ORAL SMITHKLINE BEECHAM XANAX XR 021434 2003 TABLET, EXTENDED RELEASE; ORAL PHARMACIA AND UPJOHN ZOMIG NASAL 021450 2003 SPRAY; NASAL ASTRAZENECA ADVAIR HFA 021254 2004 AEROSOL, METERED; INHALATION GLAXOSMITHKLINE ALLEGRA D 24 HOUR 021704 2004 TABLET, EXTENDED RELEASE; ORAL SANOFI AVENTIS US ARICEPT ODT 021720 2004 TABLET, ORALLY DISINTEGRATING; ORAL EISAI MEDCL RES ATROVENT HFA 021527 2004 AEROSOL, METERED; INHALATION BOEHRINGER INGELHEIM CAMPRAL 021431 2004 TABLET, DELAYED RELEASE; ORAL FOREST LABS CODEPREX 021369 2004 SUSPENSION, EXTENDED RELEASE; ORAL UCB DEPODUR 021671 2004 INJECTABLE, LIPOSOMAL; EPIDURAL SKYEPHARMA ENABLEX 021513 2004 TABLET, EXTENDED RELEASE; ORAL NOVARTIS EQUETRO 021710 2004 CAPSULE, EXTENDED RELEASE; ORAL SHIRE ESTROGEL 021166 2004 GEL, METERED; TRANSDERMAL ASCEND FAZACLO ODT 021590 2004 TABLET, ORALLY DISINTEGRATING; ORAL AVANIR PHARMS FLOVENT HFA 021433 2004 AEROSOL, METERED; INHALATION GLAXO GRP LTD FLUXID 021712 2004 TABLET, ORALLY DISINTEGRATING; ORAL SCHWARZ PHARMA FORTAMET 021574 2004 TABLET, EXTENDED RELEASE; ORAL ANDRX LABS LLC LIDOCAINE HCl, EPINEPHRINE 021486 2004 SOLUTION; IONTOPHORESIS, TOPICAL EMPI LIDOSITE TOPICAL SYSTEM KIT 021504 2004 PATCH; IONTOPHORESIS, TOPICAL VYTERIS NASACORT HFA 020784 2004 SPRAY, METERED; NASAL SANOFI AVENTIS PALLADONE 021044 2004 TABLET, EXTENDED RELEASE; ORAL PURDUE PHARMA LP PENTASA 020049 2004 CAPSULE, EXTENDED RELEASE; ORAL SHIRE PROAIR HFA 021457 2004 AEROSOL, METERED; INHALATION IVAX RES SPIRIVA 021395 2004 POWDER; INHALATION BOEHRINGER INGELHEIM VANTAS 021732 2004 IMPLANT; SUBCUTANEOUS INDEVUS VENTAVIS 021779 2004 SOLUTION; INHALATION ACTELION PHARM ABRAXANE 021660 2005 FOR SUSPENSION; IV (INFUSION) ABRAXIS BIOSCIENCE AMBIEN CR 021774 2005 TABLET, EXTENDED RELEASE; ORAL SANOFI AVENTIS US ASMANEX TWISTHALER 021067 2005 POWDER; INHALATION SCHERING CARDURA XL 021269 2005 TABLET, EXTENDED RELEASE; ORAL PFIZER CITALOPRAM HBr 021763 2005 TABLET; ORALLY DISINTEGRATING BIOVAIL LABS INTL CLARINEX D 24 HOUR 021605 2005 TABLET, EXTENDED RELEASE; ORAL SCHERING FOCALIN XR 021802 2005 CAPSULE, EXTENDED RELEASE; ORAL NOVARTIS FORTICAL 021406 2005 SPRAY, METERED; NASAL UPSHER SMITH GLUMETZA 021748 2005 TABLET, EXTENDED RELEASE; ORAL DEPOMED INC NASCOBAL 021642 2005 SPRAY, METERED; NASAL PAR PHARM NIRAVAM 021726 2005 TABLET, ORALLY DISINTEGRATING; ORAL SCHWARZ PHARMA PROQUIN XR 021744 2005 TABLET, EXTENDED RELEASE; ORAL ESPRIT PHARMA RAZADYNE ER 021615 2005 CAPSULE, EXTENDED RELEASE; ORAL ORTHO MCNEIL JANSSEN REGLAN ODT 021793 2005 TABLET, ORALLY DISINTEGRATING; ORAL ALAVEN PHARM RETISERT 021737 2005 IMPLANT; INTRAVITREAL BAUSCH AND LOMB TRAMADOL HCl ODT 021693 2005 TABLET, ORALLY DISINTEGRATING; ORAL BIOVAIL ULTRAM ER 021692 2005 TABLET, EXTENDED RELEASE; ORAL BIOVAIL LABS INTL XOPENEX HFA 021730 2005 AEROSOL, METERED; INHALATION SEPRACOR ZMAX 050797 2005 FOR SUSPENSION, EXTENDED RELEASE; ORAL PFIZER GLOBAL ABILIFY 021729 2006 TABLET, ORALLY DISINTEGRATING; ORAL OTSUKA AEROSPAN HFA 021247 2006 AEROSOL, METERED; INHALATION FOREST LABS BROVANA 021912 2006 SOLUTION; INHALATION SEPRACOR CLARINEX-D 12 HOUR 021313 2006 TABLET, EXTENDED RELEASE; ORAL SCHERING-PLOUGH COREG CR 022012 2006 CAPSULE, EXTENDED RELEASE; ORAL SB PHARMCO DAYTRANA 021514 2006 FILM, EXTENDED RELEASE; TRANSDERMAL SHIRE DUTOPROL 021956 2006 TABLET, EXTENDED RELEASE; ORAL ASTRAZENECA ELESTRIN 021813 2006 GEL, METERED; TRANSDERMAL AZUR PHARMA II EMSAM 021336 2006 FILM, EXTENDED RELEASE; TRANSDERMAL SOMERSET EXUBERA 021868 2006 POWDER; INHALATION PFIZER FENTORA 021947 2006 TABLET; BUCCAL CEPHALON FORADIL CERTIHALER 021592 2006 POWDER; INHALATION NOVARTIS IMPLANON 021529 2006 IMPLANT; IMPLANTATION ORGANON USA INC INVEGA 021999 2006 TABLET, EXTENDED RELEASE; ORAL ORTHO MCNEIL JANSSEN IONSYS 021338 2006 SYSTEM; IONTOPHORESIS, TRANSDERMAL ALZA NITROMIST 021780 2006 AEROSOL, METERED; SUBLINGUAL NOVADEL OMNARIS 022004 2006 SPRAY, METERED; NASAL ALTANA PHARMA OPANA ER 021610 2006 TABLET, EXTENDED RELEASE; ORAL ENDO PHARMS ORACEA 050805 2006 CAPSULE, DELAYED RELEASE; ORAL COLLAGENEX PHARMS ORAPRED ODT 021959 2006 TABLET, ORALLY DISINTEGRATING; ORAL MEDICIS RANEXA 021526 2006 TABLET, EXTENDED RELEASE; ORAL GILEAD SOLODYN 050808 2006 TABLET, EXTENDED RELEASE; ORAL MEDICIS SYMBICORT 021929 2006 SPRAY, METERED; INHALATION ASTRAZENECA FOR SUSPENSION, EXTENDED RELEASE; VIVITROL 021897 2006 INTRAMUSCULAR ALKERMES ZELAPAR 021479 2006 TABLET, ORALLY DISINTEGRATING; ORAL VALEANT PHARM INTL ALLEGRA ODT 021909 2007 TABLET, ORALLY DISINTEGRATING; ORAL SANOFI AVENTIS US AMLODIPINE BESYLATE 022026 2007 TABLET, ORALLY DISINTEGRATING; ORAL SYNTHON PHARMS AMRIX 021777 2007 CAPSULE, EXTENDED RELEASE; ORAL ECR CALOMIST 022102 2007 SPRAY, METERED; NASAL FLEMING DIVIGEL 022038 2007 GEL; TRANSDERMAL UPSHER SMITH EVAMIST 022014 2007 SPRAY; TRANSDERMAL KV PHARM EXELON 022083 2007 FILM, EXTENDED RELEASE; TRANSDERMAL NOVARTIS FLECTOR 021234 2007 PATCH; TOPICAL INST BIOCHEM LIALDA 022000 2007 TABLET, DELAYED RELEASE; ORAL SHIRE MIRCERA 125164 2007 SOLUTION; INJECTION HOFFMANN-LA ROCHE NEUPRO (TTS) 021829 2007 FILM, EXTENDED RELEASE; TRANSDERMAL SCHWARZ BIOSCIENCES PERFOROMIST 022007 2007 SOLUTION; INHALATION DEY SANCTURA XR 022103 2007 CAPSULE, EXTENDED RELEASE; ORAL ALLERGAN SEROQUEL XR 022047 2007 TABLET, EXTENDED RELEASE; ORAL ASTRAZENECA SIMVASTATIN 021961 2007 TABLET, ORALLY DISINTEGRATING; ORAL SYNTHON PHARMS SOMATULINE DEPOT 022074 2007 INJECTABLE; SUBCUTANEOUS BEAUFOUR IPSEN STAVZOR 022152 2007 CAPSULE,
Load more

Recommended publications
  • Absorbine Veterinary Liniment for Horses
    Doc# 03.287 Ver. 11 SAFETY DATA SHEET ABSORBINE® VETERINARY LINIMENT SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION 1.1 Trade Name (as labeled): Absorbine® Veterinary Liniment Synonyms: N/A CAS No: Mixture 1.2 Product Use: Soothes sore muscles and stiff joints 1.3 Company Name: W.F. Young Company Address: 302 Benton Dr Company Address Cont: East Longmeadow, MA 01028 Business Phone: ( 413) 526-9999 Website: www.wfyoung.com 1.4 Emergency Telephone Number: (413) 526-9999 Date of Current Revision: January 17, 2017 Date of Last Revision: August 7, 2015 SECTION 2 - HAZARD IDENTIFICATION EMERGENCY OVERVIEW: This product is a green thin liquid with an acetone odor. Health Hazards: May cause skin, eye, and respiratory system irritation. Flammabilit Hazards: This product is a flammable liquid with a flash point over 20°F (-6. 7°C). Reactivit Hazards: None. Environmental Hazards: The environmental effectsof this product have not been investigated, however release may cause long term adverse environmental effects. US DOT Symbols: EU and GHS Symbols: Signal Word: Danger! 2.1 CLASSIFICATION OF SUBSTANCE OR MIXTURE IN ACCORDANCE WITH 29 CFR 1200 (OSHA HCSl AND THE EUROPEAN UNION DIRECTIVES: This product does meet the definition of a hazardous substance or preparation as defined by 29 CFR 1910. 1200 or the European Union Council Directives 67 /548/EEC, 1999/45/EC, 1272/2008/EC and subsequent Directives. EU HAZARD CLASSIFICATIONOF INGREDIENTS PER DIRECTIVE 1272/2008/EC: IndexNumber: EC# 201-939-0 This substance is not classified in the AnnexVI of Directive 67/548/EEC EC# 200-662-2 This substance is classified in the AnnexVI of Directive 67/548/EEC Index# 606-001-00-8 Substances not listed either individually or in group entries must be self classified.
    [Show full text]
  • Inhalation Solution, USP for Oral Inhalation Use What Is Tobramycin
    PATIENT INFORMATION TOBRAMYCIN (TOE-BRA-MYE-SIN) Inhalation Solution, USP for oral inhalation use What is Tobramycin Inhalation Solution? Tobramycin inhalation solution is a prescription medicine that is used to treat people with cystic fibrosis who have a bacterial infection called Pseudomonas aeruginosa. Tobramycin inhalation solution contains an antibacterial medicine called tobramycin (an aminoglycoside). It is not known if tobramycin inhalation solution is safe and effective: in children under 6 years of age in people who have an FEV1 less than 25% or greater than 75% predicted in people who are colonized with a bacterium called Burkholderia cepacia Do not take tobramycin inhalation solution if you are allergic to tobramycin, any of the ingredients in tobramycin inhalation solution, or to any other aminoglycoside antibacterial. See the end of this Patient Information for a complete list of ingredients in tobramycin inhalation solution. Before you take tobramycin inhalation solution, tell your healthcare provider about all of your medical conditions, including if you: have or have had hearing problems (including noises in your ears such as ringing or hissing) have dizziness have or have had kidney problems have or have had problems with muscle weakness such as myasthenia gravis or Parkinson’s disease have or have had breathing problems such as wheezing, coughing, or chest tightness are pregnant or plan to become pregnant. Tobramycin inhalation solution is in a class of drugs that can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if tobramycin passes into your breast milk. are receiving aminoglycoside therapy by injection or through a vein (intravenous) while taking tobramycin inhalation solution.
    [Show full text]
  • Hydrogen Peroxide, and This Is the Same Substance That Can Be Purchased in a 32-Ounce Plastic Bottle at Walmart, for 88 Cents, Or at Walgreens for Under a $1.00
    An At-Home Treatment That Can Cure Any Virus, Including Coronavirus Originally Conceptualized, circa 1990, by Charles Farr, MD Subsequently Researched and Prescribed by Frank Shallenberger, MD Current Protocol Created by Thomas Levy, MD, JD Although COVID-19, aka coronavirus, is deadly in some select cases, and it can spread rapidly, there is a simple, very inexpensive, and highly effective treatment that can treat and rapidly resolve coronavirus and virtually any other respiratory virus. While different individuals can be expected to have variable degrees of positive response, this intervention can be anticipated to eliminate eventual fatal disease outcomes in all but the most advanced cases. As I hope you will eventually experience, the treatment works for all acute viral infections, and especially well for flu viruses of any variety. In fact, although we are constantly conditioned to not believe in anything “too good to be true,” you will never have to worry about getting a cold or the flu again because you can cure it on your own. The key ingredient in this treatment is common household 3% hydrogen peroxide, and this is the same substance that can be purchased in a 32-ounce plastic bottle at Walmart, for 88 cents, or at Walgreens for under a $1.00. Perhaps you have never heard of hydrogen peroxide therapy, but since the treatment was first championed by Dr. Charles Farr in about 1990, thousands of doctors have used this therapy for decades to conquer infections in many thousands of patients throughout the world. How and Why Hydrogen Peroxide Works Because hydrogen peroxide consists of a water molecule (H2O) with an extra oxygen atom (H2O2), it is this extra oxygen atom that makes it so deadly for viruses.
    [Show full text]
  • Inhalation Anesthesia Machine / Vaporizer / Waste Gas Maintenance
    Office of Research Office of Responsible Research Practices Institutional Animal Care and Use Committee INHALATION ANESTHESIA MACHINE / VAPORIZER / WASTE GAS MAINTENANCE Overview/Purpose To reduce risk of anesthetic gas exposure to animals and personnel, proper maintenance of anesthesia equipment, appropriate waste scavenging systems, and safe administration techniques must be employed. Preventative maintenance is key in reaching this goal. ULAR machines are maintained by ULAR while maintenance of lab owned machines is required by the research team. Personnel must be properly trained to provide safe anesthesia to animals and in the proper use and maintenance of anesthetic machines. Training is available through ULAR http://ular.osu.edu/training/animal-handling-and-technique-training/. Definition 1. Anesthesia Machine. - The entire piece of equipment that is used to deliver precise amounts of inhaled anesthetic gas and/or a carrier gas (usually air, O2 or CO2, alone or in a mix). It consists of multiple parts (precision vaporizer, carrier gas regulators, flow meters, delivery/breathing circuits and scavenge systems and possibly a rebreathing reservoir (bag). a. Rebreathing systems – for animals weighing over ~5kg b. Non-rebreathing systems – for rodents and animals weighing under ~5kg. 2. Breathing Circuit: The tubing that delivers the fresh gas/anesthetic gas mixture from the machine to the patient. a. Rebreathing circuits direct the expired gases through a soda lime canister for absorption of carbon dioxide, which are then “rebreathed” by the patient. b. Non-rebreathing circuits are designed to deliver oxygen and anesthetic gases with less resistance to breathing in small patients and have a higher fresh gas flow to remove carbon dioxide.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Nebulizers and Inhalation Drugs
    JURISDICTIONS B & C DOCUMENTATION CHECKLIST NEBULIZERS AND INHALATION DRUGS Small Volume Nebulizers (A7003, A7004, A7005) & Related Compressor (E0570) REQUIRED DOCUMENTATION Standard Written Order (original, faxed, or copied) that contains: Beneficiary’s name or Medicare Beneficiary Identifier (MBI) Order date General description of the item The description can be either a general description (e.g., wheelchair or hospital bed), a HCPCS code, a HCPCS code narrative, or a brand name/model number For equipment - In addition to the description of the base item, the SWO may include all concurrently ordered options, accessories or additional features that are separately billed or require an upgraded code (List each separately). For supplies – In addition to the description of the base item, the DMEPOS order/ prescription may include all concurrently ordered supplies that are separately billed (List each separately) Quantity to be dispensed, if applicable Treating Practitioner Name or NPI Treating Practitioner’s signature Any changes or corrections have been initialed/signed and dated by the ordering practitioner Treating practioner’s signature on the written order meets CMS Signature Requirements https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/ MLNMattersArticles/downloads/MM6698.pdf For drugs used as a supply for a DME item, the written order may include: The type of solution to be dispensed is described by either: The name of the drug and the concentration of the drug in the dispensed solution (Example: Cromolyn 20
    [Show full text]
  • Safety Data Sheet
    First issue: September 17, 2009 Revision date: October 27, 2014 SDS No. 007.636 Version: 5 SAFETY DATA SHEET In accordance with OSHA’s Hazard Communication Standard 29 CFR §1910.1200 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier: Absorbine® Veterinary Liniment Gel 1.2. Relevant identified uses of the substance or mixture and uses advised against Topical Analgesic 1.3. Details of the supplier of the safety data sheet Manufacturer/Supplier: W. F. Young, Inc. 302 Benton Drive East Longmeadow, MA 01028 Telephone number for information: 413 526 9999 E-mail: [email protected] 1.4. Emergency telephone number 413 526 9999 SECTION 2: HAZARDS IDENTIFICATION 2.1. Classification of the mixture F, Xn, Xi R10, 22, 43 2.2. Label elements Flammable Keep out of the reach of children Harmful if swallowed May product an allergic reaction 2.3. Other hazards Inhalation of vapors can cause anesthetic effect. Page 1 of 8 First issue: September 17, 2009 Revision date: October 27, 2014 SDS No. 007.636 Version: 5 SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS 3.2. Mixtures Hazardous ingredients information Component CAS Nr. EINECS / Amount DSD DSD ELINCS (%) Hazard R-Phrases Symbol Ethanola,denatured 64-17-5 200-578-6 40 - 70 F R11 Menthol 89-78-1 201-939-0 4 Choroxylenol 88-04-0 201-793-8 0.5 Xi R43 Spearmint Oil 8008-79-5 Not classified 0.5-1.0 Xi R43 Propylene Glycola 57-55-6 200-338-0 1 - 5 Other Components: Remaining components of this alcoholic mixture are proprietary, non-hazardous and/or are present at concentrations below reportable limits.
    [Show full text]
  • Inhalation Therapy - Approaches and Challenges
    Online - 2455-3891 Vol 11, Issue 4, 2018 Print - 0974-2441 Review Article INHALATION THERAPY - APPROACHES AND CHALLENGES SAYANI BHATTACHARYYA*, BHARANI S SOGALI Department of Pharmaceutics, Krupanidhi College of Pharmacy, No: 12/1 Carmelaram Road, Chikka Bellandur, Varthur, Hobli, Carmelaram Post, Bengaluru – 560 035, Karnataka, India. Email:[email protected] Received: 05 December 2017, Revised and Accepted: 02 January 2018 ABSTRACT Inhalation therapy is an effective way for local and systemic delivery of miscellaneous drugs for pulmonary and non-pulmonary diseases. The inhalation therapy aims to target specific cells or regions of the lung, bypassing the lung’s clearance mechanisms and thereby providing high retention of the drug for longer periods. It helps in improved penetration of intravenously administered antibiotics into lung parenchymal tissue and bronchial secretions, and as a result, their potential systemic toxicity is reduced when given over prolonged periods of time. The advancement in device technology supports the development of more efficient therapy in the form of delivering finer particles into the lung in large doses. Therefore, meticulous daily management of lung disease, together with prompt, aggressive treatment of exacerbations can be achieved through inhalation to preserve lung function. This review summarizes the features of inhalation delivery devices, their advantages and limitations, challenges in formulation and brief description of novel technologies currently marketed. Keywords: Lung, Inhalation, Target, Local delivery, Systemic delivery, Novel technologies. © 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i4.24117 INTRODUCTION while drug localized at the upper airways are removed by ciliated cells in the epithelial region.
    [Show full text]
  • Regulations Governing the Classification of Medical Devices (Draft)
    Regulations Governing the Classification of Medical Devices (Draft) Article 1 These Regulations are enacted pursuant to Paragraph 2, Article 3 of the Medical Devices Act (hereinafter “this Act”). Article 2 Medical devices are classified into the following categories according to their function, intended use, operating instructions, and working principle, depending on the applicable medical specialty: 1. Clinical chemistry and clinical toxicology devices 2. Hematology and pathology devices 3. Immunology and microbiology devices 4. Anesthesiology devices 5. Cardiovascular devices 6. Dental devices 7. Ear, nose, and throat devices 8. Gastroenterology and urology devices 9. General and plastic surgery devices 10. General hospital and personal use devices 11. Neurological devices 12. Obstetrical and gynecological devices 13. Ophthalmic devices 14. Orthopedic devices 15. Physical medicine devices 16. Radiology devices Article 3 Medical devices are classified into the following classes according to their risk level: 1. Class I: Low risk 2. Class II: Medium risk 3. Class III: High risk 1 Article 4 Product items of the medical device classification are specified in the Annex. In addition to rules stated in the Annex, medical devices whose function, intended use, or working principle are special may have their classification determined according to the following rules: 1. If two or more categories, classes, or product items are applicable to the same medical device, the highest class of risk level is assigned. 2. The accessory to a medical device, intended specifically by the manufacturer for use with a particular medical device, is classified the same as the particular medical device, unless otherwise specified in the Annex. 3.
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008
    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 William A. Rutala, Ph.D., M.P.H.1,2, David J. Weber, M.D., M.P.H.1,2, and the Healthcare Infection Control Practices Advisory Committee (HICPAC)3 1Hospital Epidemiology University of North Carolina Health Care System Chapel Hill, NC 27514 2Division of Infectious Diseases University of North Carolina School of Medicine Chapel Hill, NC 27599-7030 1 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 3HICPAC Members Robert A. Weinstein, MD (Chair) Cook County Hospital Chicago, IL Jane D. Siegel, MD (Co-Chair) University of Texas Southwestern Medical Center Dallas, TX Michele L. Pearson, MD (Executive Secretary) Centers for Disease Control and Prevention Atlanta, GA Raymond Y.W. Chinn, MD Sharp Memorial Hospital San Diego, CA Alfred DeMaria, Jr, MD Massachusetts Department of Public Health Jamaica Plain, MA James T. Lee, MD, PhD University of Minnesota Minneapolis, MN William A. Rutala, PhD, MPH University of North Carolina Health Care System Chapel Hill, NC William E. Scheckler, MD University of Wisconsin Madison, WI Beth H. Stover, RN Kosair Children’s Hospital Louisville, KY Marjorie A. Underwood, RN, BSN CIC Mt. Diablo Medical Center Concord, CA This guideline discusses use of products by healthcare personnel in healthcare settings such as hospitals, ambulatory care and home care; the recommendations are not intended for consumer use of the products discussed. 2
    [Show full text]
  • Saudi FDA Products Classification Guidance
    Saudi FDA Products Classification Guidance دليل تصنيف المنتجات في الهيئة العامة للغذاء والدواء Version 4.0 Date of publication 21/4/2020 Date of implementation 21/5/2020 1 Saudi FDA Products Classification Guidance Version 4.0 Saudi Food & Drug Authority Kingdom of Saudi Arabia Please review and send your comments and suggestions to [email protected] Please visit SFDA’s website at www.sfda.gov.sa for the latest update 2 Saudi Food & Drug Authority Vision and Mission الرؤية وا لرسالة Vision To be a leading international science-based regulator to protect and promote public health. الرؤي ة أن تكو ن هي ئة رائد ة عالمي ا تستن د إلى أسس علمية لتعزيز وحما ية الصحة العامة Mission Protecting the community through regulations and effective controls to ensure the safety of food, drugs, medical devices, cosmetics, pesticides and feed. الرسالة حماية المجتمع من خﻻل تشريعات ومنظومة رقابية فعالة لضمان سﻻمة الغذاء والدواء واﻷجهزة الطبية ومنتجات التجميل والمبيدات واﻷع ﻻف 3 Document Control Version Author Date Comments 3.0 Products Classification Department 11/04/2019 Final 3.1 Products Classification Department 21/10/2019 Final 4.0 Products Classification Department 21/4/2020 Draft 4 Table of Contents 1. INTRODUCTION ............................................................................................................................... 6 1.1 OBJECTIVES ................................................................................................................................... 6 1.2 BACKGROUND ..............................................................................................................................
    [Show full text]